DHANSA LABS LIMITED

(Formerly known as Ambey Laboratories Limited)
Reg. Office: Ground Floor, Property No.555 Tarla Mohalla, Ghitorni, South-West Delhi-110030 India
CIN: L74899DL1985PLC020490
Contact: 9899664458, Email: accountho@ambeylab.com
www.dhansalabs.com

Date: 14.08.2026

To,

The Head – Listing & Compliance
National Stock Exchange of India Ltd.,
Exchange Plaza, C-1, Block G, Bandra Kurla Complex,
Bandra (E) Mumbai – 400 051

Symbol: DHANSA
ISIN : INE0M3I01029

Sub: Outcome of the Board Meeting held on 14th August 2026.

Ref: Regulation 30 (read with Part A of Schedule III) and Regulation 33 and other applicable Regulations of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Dear Sir/ Madam,

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI LODR"), this is to inform you that the Board of Directors of the Company, at its meeting held today, i.e., on Friday, August 14, 2026, has considered and approved the following items:

1. **Unaudited Financial Results (Standalone and Consolidated) for the 1st quarter (April to June) of Financial Year 2026-27**

   Pursuant to Regulation 33 of the SEBI (LODR) Regulations, we hereby submit the Unaudited Financial Results (Standalone and Consolidated) of the Company for the 1st quarter (April to June) of the Financial Year 2026-27, along with the Limited Review Report issued by the Statutory Auditor of the Company. "Annexure-A".

   Further, an extract of the aforementioned Unaudited Financial Results (Standalone and Consolidated) shall be published in newspapers in accordance with the provisions of the SEBI LODR Regulations.

   The aforesaid Unaudited Financial Results (Standalone and Consolidated) will be uploaded on the Company's website at https://dhansalabs.com/ and will also be available on the website of NSE at https://www.nseindia.com/ for the benefit of shareholders and investors.

2. **Statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement, etc. "Annexure-B".**

3. **Amendment and Adoption of Various Policies pursuant to the Applicability of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, consequent to the increase in the paid-up share capital of the Company beyond ₹25 Crore:**

   a. Policy For Determination of Material Subsidiary

b. Preservation of Documents & Archival Policy
c. Policy For Determination of Materiality of Events or Information
d. Remuneration Policy
e. Code of Practices and Procedures for Fair Disclosure of Unpublished Price Sensitive Information

4. Change in Email ID of the Company Secretary/Compliance Officer

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI LODR"), we wish to inform you that email ID of the Company Secretary/Compliance Officer of the Company has been changed, with immediate effect. The details are as under:

Name of Company Secretary / Compliance Officer	Himanshu Kukreja
Existing Mail id	cs@ambeylab.com
New Mail id	cs@dhansagroup.com

The Board Meeting commenced at 11:30 A.M. and concluded at 12:50 P.M.

Kindly take the above information on record and oblige.

Thanking You,

For Dhansa Labs Limited

Himanshu Kukreja Digitally signed by Himanshu Kukreja
Date: 2026.08.14 12:57:56 +05'30'

Himanshu Kukreja
Company Secretary & Compliance Officer
Membership No: A64853

Enc: aa

KAPISH JAIN & ASSOCIATES
CHARTERED ACCOUNTANTS

F.R.N. 022743N

Head Office: 504, B-Wing, Statesman House, 148, Barakhamba Road, New Delhi - 110001 | Phone : +91-11-43708987
Mobile : +91 9971 921466 | Email : ca.kapish@gmail.com | Website : www.kapishjainassociates.com; www.cakja.com

Independent Auditor's Review Report on Standalone Unaudited Financial Results for the Quarter Ended 30 June 2026 of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

Review Report to
The Board of Directors
Dhansa Labs Limited
(Formerly known as Ambey Laboratories Limited)

1. We have reviewed the accompanying Statement of Standalone Unaudited Financial Results ("Statement") of **Dhansa Labs Limited** (Formerly known as Ambey Laboratories Limited) ("the Company") for the quarter ended 30 June 2026 ("the Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the "Regulation") as amended, including relevant circulars issued by the SEBI from time to time.

2. This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the generally accepted accounting principles in India ("GAAP") and in compliance with the applicable Accounting Standard as prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the statements are free of material misstatements. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the Regulation, to the extent applicable.

4. Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with the generally accepted accounting principles in India ("GAAP") and in compliance with the applicable Accounting Standard as specified under section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of the Regulation, read with Circular, including the manner in which it is to be disclosed, or that it contains any material misstatement.

5. During the year ended 31 March 2026, the Company allotted 1,08,69,565 convertible equity warrants on preferential basis at an issue price of Rs. 46/- per warrant, aggregating to Rs. 4,999.99 lakhs, in accordance with Section 42 and Section 62(1)(c) of the Companies Act, 2013 and applicable provisions of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018.

Kapish Jain & Associates
NEW DELHI
Chartered Accountants

Against the aforesaid warrants, the Company has received an aggregate amount of Rs. 2,161.53 lakhs up to 30 June 2026 towards warrant subscription money/part consideration. During the quarter ended 30 June 2026, 19,56,521 warrants were converted into equity shares. Accordingly, the balance warrants remain outstanding and are pending conversion as at 30 June 2026.

The money received against these warrants has been utilized for the purposes detailed in the table below.

(All amounts in Rs. lacs, unless otherwise stated)

Object of issue	Total issue size	Amount received till 30 June 2026	Amount utilized till 30 June 2026	Amount unutilized till 30 June 2026	Deviation (if any)
The funds were utilized towards general corporate purposes, advances for plant and machinery, supporting ongoing capital expenditure; and land-related advances.	4999.99	2161.53	2161.53	-	N/A
Total	**4999.99**	**2161.53**	**2161.53**	-	**N/A**

Our conclusion on the Statement is not modified in respect of the above matter.

For **Kapish Jain & Associates,**
Chartered Accountants
Firm Registration No. 022743N

Kapish Jain & Associates
NEW DELHI
Chartered Accountants

CA Kapish Jain
Partner
M. No.: 514162
UDIN: 26514162XFXHPU5190
Place: New Delhi
Date: 14th August 2026

DHANSA LABS LIMITED
(Formerly known as Ambey Laboratories Limited)
Regd. Office : Ground Floor,Property No.555 Tarla Mohalla,Ghitorni, South West Delhi, Delhi, India, 110030
Corp. Office : B18/9, Dlf Phase -1 Sector 26A, Gurugram-122002, Gurugram, Haryana, India, 122002
CIN: L74899DL1985PLC020490, Email:cs@ambeylab.com

STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS
FOR THE QUARTER ENDED 30 JUNE 2026

(All amounts in Rs. lacs, unless stated otherwise)

Sl. No	Particulars	Querter ended			Year ended
		30.06.2026 (Unaudited)	31.03.2026 (Audited)	30.06.2025 (Unaudited)	31.03.2026 (Audited)
1	**Income**				
	a) Revenue from operations	3,056.29	4,053.73	2,828.96	14,153.72
	b) Other income	63.34	107.91	2.04	151.30
	Total income	3,119.63	4,161.64	2,831.00	14,305.02
2	**Expenses**				
	a) Cost of material consumed	2,891.70	3,341.35	3,165.86	12,980.30
	b) Changes in inventories of work-in-progress, finished goods	(194.07)	402.68	(732.52)	(339.69)
	c) Employee benefits expense	30.32	13.12	30.38	115.78
	d) Finance costs	70.61	37.91	99.67	262.39
	e) Depreciation and amortisation expense	44.15	54.32	54.74	219.78
	f) Other expenses	62.97	63.90	78.94	305.83
	Total expenses	2,905.68	3,913.28	2,697.07	13,544.39
3	**Profit/(loss) before exceptional item & tax (1-2)**	213.95	248.36	133.93	760.63
4	Exceptional Items	-	-	-	-
5	**Profit/(loss) before tax (3-4)**	213.95	248.36	133.93	760.63
6	Tax expense				
	-Current tax	59.16	79.74	22.36	192.11
	-Deferred tax charge/ (benefit)	20.92	(40.32)	14.19	(4.74)
	-MAT credit entitlement	-	-	(22.36)	-
	Tax expense	80.08	39.42	14.19	187.37
7	**Net Profit/(Loss) after tax (5-6)**	133.87	208.94	119.74	573.26
8	**Paid-up Equity Share Captial (Face value of Rs.10/- each)**	2,690.33	2,494.68	2,494.68	2,494.68
9	Reserves (excluding revaluation reserve)				4,663.60
10	**Earnings per equity share**				
	[Nominal value per share Rs. 10] (not annualised, except year end)				
	Basic earnings per share (in ₹)	0.51	0.84	0.48	2.30
	Diluted earnings per share (in ₹)	0.51	0.84	0.48	2.30

Notes:-

1 The above Financial Results were reviewed by the Audit Committee and were thereafter approved by the Board of Directors at their meeting held on 14th August, 2026

2 The above results have been prepared in accordance with the recognition and measurement principles of Accounting Standard ("AS"), prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India.

3 The Company primarily engaged in the business of manufacturing and distribution of agro and home hygiene products. Hence, the Company has a single reportable segment as per the Accounting Standard - 17.

4 During the year ended 31 March 2026, the Company allotted 1,08,69,565 convertible equity warrants on preferential basis at an issue price of Rs. 46/- per warrant, aggregating to Rs. 4,999.99 lakhs, in accordance with Section 42 and Section 62(1)(c) of the Companies Act, 2013 and applicable provisions of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018.

Against the aforesaid warrants, the Company has received an aggregate amount of Rs. 2,161.53 lakhs up to 30 June 2026 towards warrant subscription money/part consideration. During the quarter ended 30 June 2026, 19,56,521 warrants were converted into equity shares. Accordingly, the balance warrants remain outstanding and are pending conversion as at 30 June 2026.

The money received against these warrants has been utilized for the purposes detailed in the table below.

(All amounts in Rs. lacs, unless otherwise stated)

Object of issue	Total issue size	Amount received till 30 June 2026	Amount utilized till 30 June 2026	Amount unutilized as on 30 June 2026	Deviation (if any)
The funds were utilised towards general corporate purposes, advances for plant and machinery, supporting ongoing capital expenditure; and land-related advances.	4999.99	2161.53	2161.53	-	NA
Total	4999.99	2161.53	2161.53	-	NA

For and on behalf of the Board of Directors of
Dhansa Labs Limited
(Formely known as Ambey laboratories limited)

Archit Gupta
Whole Time Director
DIN 00378409

Date: 14th August 2026
Place: Gurugram

Independent Auditor's Review Report on Consolidated Unaudited Financial Results for the quarter ended 30 June 2026 of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

Review Report to
The Board of Directors
Dhansa Labs Limited
(Formerly known as Ambey Laboratories Limited)

1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of **Dhansa Labs Limited (Formerly known as Ambey Laboratories Limited)** ("the Holding Company"), its subsidiaries (the Holding Company and its subsidiaries together referred to as the "Group") for the quarter ended 30 June 2026 ("the Statement") attached herewith, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the "Regulation") as amended, including relevant circulars issued by the SEBI from time to time.

2. This statement, which is the responsibility of the Holding Company's Management and approved by the Holding Company's Board of Directors, has been compiled from the related unaudited interim financial information which has been prepared in accordance with the recognition and measurement principles laid down in the Accounting Standard 25 "Interim Financial Reporting" (AS 25), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the statements are free of material misstatements. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. The Statement includes the results of the following entities:

S.No.	Name of the entity	Relation
1	Dhansa Green Energy Private Limited (w.e.f. August 14, 2025)	Subsidiary Company
2	Dhansa Biofuels Power Private Limited (w.e.f. January 27, 2026)	Subsidiary Company

5. We did not review the interim financial results/information of the above subsidiaries included in the Statement, whose financial statements/financial information reflect total revenue of Rs. Nil (before consolidation adjustment) and total net profit / (loss) after tax of Rs. (2.20) lacs (before consolidation adjustment) for the quarter ended 30 June 2026 as considered in the unaudited consolidated financial results which have been reviewed by their respective independent auditors. The independent auditors' reports on financial statements/ financial information of these entities have been furnished to us by the management.

Kapish Jain & Associates
NEW DELHI
Chartered Accountants

Our conclusion on the consolidated financial results, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the reports of such auditors and the procedures performed by us are as stated in paragraph above.

Our conclusion on the consolidated unaudited financial results is not modified in respect of the above matters with respect to our reliance on the work done and the reports of the other auditors.

6. Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards specified under section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of the Regulation, read with Circular, including the manner in which it is to be disclosed, or that it contains any material misstatement.

7. During the year ended 31 March 2026, the Holding Company allotted 1,08,69,565 convertible equity warrants on preferential basis at an issue price of Rs. 46/- per warrant, aggregating to Rs. 4,999.99 lakhs, in accordance with Section 42 and Section 62(1)(c) of the Companies Act, 2013 and applicable provisions of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018.

   Against the aforesaid warrants, the Holding Company has received an aggregate amount of Rs. 2,161.53 lakhs up to 30 June 2026 towards warrant subscription money/part consideration. During the quarter ended 30 June 2026, 19,56,521 warrants were converted into equity shares. Accordingly, the balance warrants remain outstanding and are pending conversion as at 30 June 2026.

   The money received against these warrants has been utilized for the purposes detailed in the table below.

(All amounts in Rs. lacs, unless otherwise stated)

Object of issue	Total issue size	Amount received till 30 June 2026	Amount utilized till 30 June 2026	Amount unutilized as on 30 June 2026	Deviation (if any)
The funds were utilized towards general corporate purposes, advances for plant and machinery, supporting ongoing capital expenditure; and land-related advances.	4999.99	2161.53	2161.53	-	N/A
Total	**4999.99**	**2161.53**	**2161.53**	-	**N/A**

Our conclusion on the Statement is not modified in respect of the above matter.

For **Kapish Jain & Associates,**
Chartered Accountants
Firm Registration No. 022743N

Kapish Jain & Associates Chartered Accountants NEW DELHI

CA Kapish Jain
Partner
M. No.: 514162
UDIN: 26514162KCTHZC4347
Place: New Delhi
Date: 14th August 2026

DHANSA LABS LIMITED
(Formerly known as Ambey Laboratories Limited)
Regd. Office : Ground Floor,Property No.555 Tarla Mohalla,Ghitorni, South West Delhi, Delhi, India, 110030
Corp. Office : B18/9, Dlf Phase -1 Sector 26A, Gurugram-122002, Gurugram, Haryana, India, 122002
CIN: L74899DL1985PLC020490, Email:cs@ambeylab.com

CONSOLIDATED STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30 JUNE 2026

(All amounts in Rs. lacs, unless otherwise stated)

Sl. No	Particulars	Querter ended			Year ended
		30.06.2026	31.03.2026	30.06.2025	31.03.2026
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
1	**Income**				
	a) Revenue from operations	3,056.29	4,053.73	-	14,153.72
	b) Other income	3.27	87.56	-	130.96
	Total income	**3,059.56**	**4,141.29**	-	**14,284.68**
2	**Expenses**				
	a) Cost of material consumed	2,891.70	3,341.35	-	12,980.30
	b) Changes in inventories of work-in-progress, finished goods	(194.07)	402.68	-	(339.69)
	c) Employee benefits expense	30.32	13.12	-	115.78
	d) Finance costs	70.61	37.91	-	262.39
	e) Depreciation and amortisation expense	44.15	54.32	-	219.78
	f) Other expenses	64.18	52.10	-	306.49
	Total expenses	**2,906.89**	**3,901.48**	-	**13,545.05**
3	**Profit/(loss) before exceptional item & tax (1-2)**	**152.67**	**239.81**	-	**739.63**
4	Exceptional Items				-
5	**Profit/(loss) before tax (3-4)**	**152.67**	**239.81**	-	**739.63**
6	Tax expense				
	Current tax	59.16	79.74	-	192.11
	Deferred tax charge/ (benefit)	20.92	(40.32)	-	(4.74)
	MAT credit entitlement	-	-	-	-
	Tax expense	**80.08**	**39.42**	-	**187.37**
7	**Net Profit/(Loss) after tax (5-6)**	**72.59**	**200.39**	-	**552.26**
8	**Paid-up Equity Share Captial (Face value of Rs.10/- each)**	2,690.33	2,494.68	-	2,494.68
9	Reserves (excluding revaluation reserve)				4,642.61
10	**Earnings per equity share**				
	Basic earnings per share (in ₹)	0.28	0.80	-	2.21
	Diluted earnings per share (in ₹)	0.28	0.80	-	2.21

Notes:-

1 The above Financial Results were reviewed by the Audit Committee and were thereafter approved by the Board of Directors at their meeting held on 14 August, 2026.

2 The above results have been prepared in accordance with the recognition and measurement principles of Accounting Standard ("AS"), prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India.

3 The Holding Company primarily engaged in the business of manufacturing and distribution of agro and home hygiene products. Hence, the Company has a single reportable segment as per the Accounting Standard - 17.

DHANSA LABS LIMITED

4 During the year ended 31 March 2026, the Holding Company allotted 1,08,69,565 convertible equity warrants on preferential basis at an issue price of Rs. 46/- per warrant, aggregating to Rs. 4,999.99 lakhs, in accordance with Section 42 and Section 62(1)(c) of the Companies Act, 2013 and applicable provisions of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018.

Against the aforesaid warrants, the Holding Company has received an aggregate amount of Rs. 2,161.53 lakhs up to 30 June 2026 towards warrant subscription money/part consideration. During the quarter ended 30 June 2026, 19,56,521 warrants were converted into equity shares. Accordingly, the balance warrants remain outstanding and are pending conversion as at 30 June 2026.

The money received against these warrants has been utilized for the purposes detailed in the table below.

(All amounts in Rs. lacs, unless otherwise stated)

Object of issue	Total issue size	Amount received till 30 June 2026	Amount utilized till 30 June 2026	Amount unutilized as on 30 June 2026	Deviation (if any)
The funds were utilised towards general corporate purposes, advances for plant and machinery, supporting ongoing capital expenditure; and land-related advances.	4999.99	2161.53	2161.53	-	NA
Total	4999.99	2161.53	2161.53	-	NA

5 The Consolidated financial results for the quarter ended on 30 June 2026 includes the following entities of the Group :

S.no.	Name of the entity	Relation
1	Dhansa Green Energy Private Limited (w.e.f. 14 August 2025)	Subsidiary Company
2	Dhansa Biofules Power Private Limited (w.e.f. 27 January 2026)	Subsidiary Company

6 The Holding Company did not have any subsidiary during the quarter ended 30 June 2025. Accordingly, there was no Group requiring consolidation during the corresponding quarter and, consequently, comparative consolidated financial results for the quarter ended 30 June 2025 have not been presented.

The consolidated financial results for the quarter ended 30 June 2026 include the financial results of the subsidiaries as mentioned in Note 5 above. Further, the consolidated financial results for the year ended 31 March 2026 include the financial results of the subsidiaries from the respective dates on which they became subsidiaries of the Company, as stated in Note 5 above.

For and on behalf of the Board of Directors of
Dhansa Labs Limited
(Formely known as Ambey laboratories limited)

DHANSA LABS LIMITED

Archit Gupta
Whole Time Director
DIN 00378409

Date: 14 August 2026
Place: Gurugram

DHANSA LABS LIMITED

(Formerly known as Ambey Laboratories Limited)
Reg. Office: Ground Floor, Property No.555 Tarla Mohalla, Ghitorni, South-West Delhi-110030 India
CIN: L74899DL1985PLC020490
Contact: 9899664458, Email: accountho@ambeylab.com
www.dhansalabs.com

Annexure B

Statement of Deviation/Variation in the utilization of funds raised

Amount in Lakhs

Name of listed entity	Dhansa Labs Limited (Formerly known as Ambey Laboratories Limited)
Mode of Fundraising	Preferential Issue
Date of Raising Funds	26th July, 2025
Amount Raised	Rs. 2161.53/-
Report filed for the Quater ended	30th June, 2026
Monitoring Agency	Not Applicable
Monitoring Agency Name, if applicable	Not Applicable
Is there a Deviation / Variation in use of funds raised	No
If Yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders	Not Applicable
If Yes, Date of shareholder Approval	Not Applicable
Explanation for the Deviation/Variation	Not Applicable
Comments of the Audit Committee after review	Not Applicable
Comments of the auditor, if any	Not Applicable

Deviation or variation could mean:

(a) Deviation in the objects or purposes for which the funds have been raised or

(b) Deviation in the amount of funds actually utilized as against what was originally disclosed or

(c) Change in terms of a contract referred to in the fund-raising document i.e., letter of offer, etc

DHANSA LABS LIMITED

(Formerly known as Ambey Laboratories Limited)
Reg. Office: Ground Floor, Property No.555 Tarla Mohalla, Ghitorni, South-West Delhi-110030 India
CIN: L74899DL1985PLC020490
Contact: 9899664458, Email: accountho@ambeylab.com
www.dhansalabs.com

Original Object	**Modified Objective if aby**	**Original Allocation**	**Modified allocation, if any**	**Funds Utilized**	**Amount of Deviation/Variation for the according quarter to applicable object**	**Remark if any**
The funds were utilized towards general corporate purposes, advances for plant and machinery, supporting ongoing capital expenditure; and land related advances.	Not Applicable	4999.99	Not Applicable	2161.53	Not Applicable	None
Total		**4999.99**		2161.53		

Kindly take the above information for your records.

For Dhansa Labs Limited

Himanshu Kukreja

Digitally signed by Himanshu Kukreja
Date: 2026.08.14 12:59:25 +05'30'

Himanshu Kukreja
Company Secretary & Compliance Officer
Membership No: A64853